1. Home
  2. UVV vs NRIX Comparison

UVV vs NRIX Comparison

Compare UVV & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UVV
  • NRIX
  • Stock Information
  • Founded
  • UVV 1886
  • NRIX 2009
  • Country
  • UVV United States
  • NRIX United States
  • Employees
  • UVV N/A
  • NRIX N/A
  • Industry
  • UVV Farming/Seeds/Milling
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • UVV Industrials
  • NRIX Health Care
  • Exchange
  • UVV Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • UVV 1.3B
  • NRIX 1.4B
  • IPO Year
  • UVV N/A
  • NRIX 2020
  • Fundamental
  • Price
  • UVV $52.40
  • NRIX $18.62
  • Analyst Decision
  • UVV
  • NRIX Strong Buy
  • Analyst Count
  • UVV 0
  • NRIX 17
  • Target Price
  • UVV N/A
  • NRIX $31.06
  • AVG Volume (30 Days)
  • UVV 132.8K
  • NRIX 655.6K
  • Earning Date
  • UVV 02-11-2025
  • NRIX 01-28-2025
  • Dividend Yield
  • UVV 6.13%
  • NRIX N/A
  • EPS Growth
  • UVV 5.05
  • NRIX N/A
  • EPS
  • UVV 4.86
  • NRIX N/A
  • Revenue
  • UVV $2,827,901,000.00
  • NRIX $54,549,000.00
  • Revenue This Year
  • UVV N/A
  • NRIX $5.98
  • Revenue Next Year
  • UVV N/A
  • NRIX $9.50
  • P/E Ratio
  • UVV $10.84
  • NRIX N/A
  • Revenue Growth
  • UVV 6.40
  • NRIX N/A
  • 52 Week Low
  • UVV $45.19
  • NRIX $8.11
  • 52 Week High
  • UVV $59.13
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • UVV 47.44
  • NRIX 42.84
  • Support Level
  • UVV $51.63
  • NRIX $19.24
  • Resistance Level
  • UVV $54.29
  • NRIX $20.50
  • Average True Range (ATR)
  • UVV 1.23
  • NRIX 1.00
  • MACD
  • UVV 0.28
  • NRIX 0.08
  • Stochastic Oscillator
  • UVV 49.89
  • NRIX 24.67

About UVV Universal Corporation

Universal Corp is a global leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segment includes Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Share on Social Networks: